Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F (2025)
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Blood Cancer J, 15 (1), 214
DOI 10.1038/s41408-025-01407-5, PubMed 41429779

Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C, Remen N, Osnes L, Stokke C, Connelly JP, Revheim MR, Schjesvold F (2025)
Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET)
Clin Lymphoma Myeloma Leuk (in press)
DOI 10.1016/j.clml.2025.10.020, PubMed 41314938

van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CLBM, Broijl A, Touzeau C, Manier S, Hajek R, Bila J, Seval GC et al. (2025)
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Hemasphere, 9 (11), e70260
DOI 10.1002/hem3.70260, PubMed 41306326